Fisher Asset Management LLC Sells 81,799 Shares of Agios Pharmaceuticals, Inc. $AGIO

Fisher Asset Management LLC decreased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 8.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 877,540 shares of the biopharmaceutical company’s stock after selling 81,799 shares during the quarter. Fisher Asset Management LLC owned approximately 1.51% of Agios Pharmaceuticals worth $29,187,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals during the 1st quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Agios Pharmaceuticals by 16.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 320 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Agios Pharmaceuticals by 16.2% in the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 499 shares during the period. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals in the first quarter valued at approximately $133,000. Finally, CWM LLC increased its position in Agios Pharmaceuticals by 218.6% during the 2nd quarter. CWM LLC now owns 5,286 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 3,627 shares during the period.

Insider Transactions at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 3,651 shares of the stock in a transaction on Friday, September 26th. The stock was sold at an average price of $36.77, for a total value of $134,247.27. Following the transaction, the chief financial officer directly owned 33,870 shares in the company, valued at $1,245,399.90. This trade represents a 9.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Theodore James Jr. Washburn sold 8,546 shares of the business’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $36.87, for a total transaction of $315,091.02. Following the sale, the insider owned 868 shares of the company’s stock, valued at $32,003.16. This trade represents a 90.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 16,099 shares of company stock valued at $620,092 over the last ninety days. 4.93% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. HC Wainwright dropped their price target on shares of Agios Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating on the stock in a research report on Thursday, November 20th. Leerink Partners raised shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their price target for the company from $40.00 to $34.00 in a research report on Thursday, November 20th. JPMorgan Chase & Co. decreased their price target on Agios Pharmaceuticals from $37.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, November 21st. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday. Finally, Zacks Research raised Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.78.

Agios Pharmaceuticals Trading Down 3.1%

Shares of NASDAQ AGIO opened at $26.98 on Wednesday. The firm has a market capitalization of $1.57 billion, a P/E ratio of -3.85 and a beta of 0.87. The firm’s 50-day moving average price is $38.62 and its 200-day moving average price is $36.90. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $62.45.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The business had revenue of $12.88 million during the quarter, compared to analyst estimates of $10.49 million. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The firm’s revenue was up 43.3% compared to the same quarter last year. During the same period in the previous year, the company posted $16.22 EPS. Equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.